Table 2. Postdiagnosis menopausal symptoms in association with breast cancer recurrence by menopausal status, SBCSS (n=4,842).
|
Menopausal status
|
||||||||
|---|---|---|---|---|---|---|---|---|
| Experience with menopausal symptoms |
Premenopausal, n=2,455
|
Postmenopausal, n=2,387
|
||||||
| Events | HRa (95% CI) | HRb (95% CI) | Events | HRa (95% CI) | HRb (95% CI) | P intera | P interb | |
| Any menopausal symptomc | ||||||||
| No | 126 | 1.00 (reference) | 1.00 (reference) | 218 | 1.00 (reference) | 1.00 (reference) | ||
| Yes | 209 | 0.82 (0.65-1.03) | 0.83 (0.66-1.04) | 167 | 1.01 (0.82-1.25) | 1.03 (0.83-1.27) | 0.19 | 0.19 |
| Hot flashes | ||||||||
| No | 168 | 1.00 (reference) | 1.00 (reference) | 266 | 1.00 (reference) | 1.00 (reference) | ||
| Yes | 167 | 0.77 (0.62-0.96) | 0.78 (0.63-0.98) | 119 | 1.01 (0.80-1.27) | 1.03 (0.82-1.30) | 0.11 | 0.10 |
| Night sweats | ||||||||
| No | 199 | 1.00 (reference) | 1.00 (reference) | 279 | 1.00 (reference) | 1.00 (reference) | ||
| Yes | 136 | 0.88 (0.70-1.10) | 0.88 (0.71-1.11) | 106 | 1.00 (0.79-1.25) | 1.00 (0.79-1.26) | 0.48 | 0.51 |
| Vaginal dryness | ||||||||
| No | 306 | 1.00 (reference) | 1.00 (reference) | 357 | 1.00 (reference) | 1.00 (reference) | ||
| Yes | 29 | 0.89 (0.61-1.32) | 0.92 (0.62-1.35) | 28 | 1.11 (0.75-1.64) | 1.11 (0.75-1.65) | 0.38 | 0.38 |
| No. of menopausal symptoms | ||||||||
| 0 | 126 | 1.00 (reference) | 1.00 (reference) | 218 | 1.00 (reference) | 1.00 (reference) | ||
| 1 | 103 | 0.93 (0.71-1.21) | 0.93 (0.71-1.22) | 94 | 1.04 (0.81-1.34) | 1.06 (0.82-1.36) | ||
| ≥2 | 106 | 0.73 (0.56-0.96) | 0.74 (0.57-0.97) | 73 | 0.97 (0.73-1.28) | 0.98 (0.74-1.30) | 0.27 | 0.28 |
a
HR: Adjusted for age at diagnosis (continuous); education (categories); number of pregnancies (categories); marital status; history of chronic disease (Charlson comorbidity score 0/≥1); self-reported quality of life (categories); received radiotherapy, chemotherapy, or immunotherapy; TNM, ER and PR status and P-interactiona across subgroups by menopausal status
b
HR: Additionally adjusted for BMI (continuous), tamoxifen use, soy isoflavone intake (continuous) and P-interactionb across subgroups by menopausal status
c
Includes hot flashes, night sweats, and/or vaginal dryness
Note: Multivariate HRs and their corresponding 95% CIs were derived from Cox proportional hazards models, using age as the time scale in all analyses